Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 14010-14017
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.14010
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.14010
Table 1 Clinical characteristics between the control group and the nonalcoholic fatty liver disease group n (%)
| Item | Control | NAFLD | P value | Frequency of disorders in NAFLD group |
| Gender (n) | -- | |||
| Male | 200 | 200 | 1.0 | -- |
| Female | 100 | 100 | 1.0 | -- |
| Age (yr) | 39.5 ± 9.1 | 40.7 ± 9.7 | 0.11 | -- |
| BMI (kg/m2) | 22.1 ± 2.8 | 26.3 ± 4.2 | < 0.001 | 186 (62.0) |
| Blood pressure (mmHg) | -- | -- | -- | 64 (21.3) |
| Systolic pressure | 119 ± 13 | 127 ± 13 | < 0.001 | -- |
| Diastolic pressure | 75 ± 10 | 82 ± 9 | < 0.001 | -- |
| HDL (mmol/L) | -- | -- | -- | 128 (42.7) |
| Male | 1.4 ± 0.2 | 1.1 ± 0.2 | < 0.001 | 107 (53.5) |
| Female | 1.4 ± 0.2 | 1.3 ± 0.3 | < 0.001 | 21 (21.0) |
| Total cholesterol (mmol/L) | 4.7 ± 0.5 | 5.4 ± 1.0 | < 0.001 | 122 (40.7) |
| TG (mmol/L) | 1.0 ± 0.5 | 2.5 ± 2.5 | < 0.001 | 119 (39.7) |
| UA (μmol/L) | -- | -- | -- | 104 (34.7) |
| Male | 335.3 ± 51.2 | 415.5 ± 97.2 | < 0.001 | 89 (44.5) |
| Female | 241.3 ± 39.5 | 324.0 ± 83.6 | < 0.001 | 15 (15.0) |
| LDL (mmol/L) | 2.7 ± 0.5 | 3.3 ± 0.9 | < 0.001 | 90 (30.0) |
| FPI (μU/mL) | 6.0 ± 3.1 | 10.62 ± 4.5 | < 0.001 | -- |
| HOMA-IR | 1.2 ± 0.7 | 2.4 ± 1.2 | < 0.001 | 74 (24.7) |
| FPG (mmol/L) | 4.8 ± 0.5 | 5.3 ± 1.1 | < 0.001 | 67 (22.3) |
| ALT (U/L) | 19.0 ± 8.7 | 42.1 ± 32.6 | < 0.001 | 114 (38.0) |
| AST (U/L) | 24.1 ± 4.9 | 33.1 ± 14.8 | < 0.001 | 148 (49.3) |
Table 2 Association between Apolipoprotein C3 (-455T>C) polymorphism and nonalcoholic fatty liver disease susceptibility n (%)
Table 3 Correlation between Apolipoprotein C3 (-455T>C) polymorphism and insulin resistance, impaired glucose tolerance in the nonalcoholic fatty liver disease group n (%)
Table 4 Correlation between Apolipoprotein C3 (-455T>C) polymorphism and hypertension, dyslipidemia in the nonalcoholic fatty liver disease group n (%)
| Genotype | Metabolic component | P value | Adjusted OR (95%CI) | |
| Non-hypertension | Hypertension | |||
| TT | 82 (34.7) | 12 (18.8) | - | 1 |
| TC | 102 (43.2) | 29 (45.3) | 0.041 | 2.16 (1.02-4.57)1 |
| CC | 52 (22.1) | 23 (35.9) | 0.0032 | 3.42 (1.53-7.60)2 |
| Non-hypertriglyceridemia | Hypertriglyceridemia | |||
| TT | 71 (39.3) | 23 (19.3) | - | 1 |
| TC | 77 (42.5) | 54 (45.4) | 0.021 | 2.03 (1.12-3.68)1 |
| CC | 33 (18.2) | 42 (35.3) | < 0.0012 | 3.80 (1.95-7.41)2 |
| Normal HDL | Low HDL | |||
| TT | 63 (36.6) | 31 (24.2) | - | 1 |
| TC | 75 (43.6) | 56 (43.8) | 0.301 | 1.36 (0.76 -2.42)1 |
| CC | 34 (19.8) | 41 (32.0) | 0.012 | 2.34 (1.21 -4.52)2 |
| Non-hypercholesterolemia | Hypercholesterolemia | |||
| TT | 57 (32.0) | 37 (30.3) | - | 1 |
| TC | 81 (45.5) | 50 (41.0) | 0.521 | - |
| CC | 40 (22.5) | 35 (28.7) | 0.202 | - |
| Normal LDL | Increased LDL | |||
| TT | 65 (31.0) | 29 (32.2) | - | 1 |
| TC | 89 (42.3) | 42 (46.7) | 0.411 | - |
| CC | 56 (26.7) | 19 (21.1) | 0.332 | - |
Table 5 Apolipoprotein C3 (-455T>C) polymorphism among different ethnicities: data from the literature n (%)
| Ref. | Ethnicity | Genotype of APOC3 (-455T>C) | ||
| TT | TC | CC | ||
| Kozlitina et al[10] | African Americans | 106 (8.7) | 484 (39.9) | 623 (51.4) |
| Kozlitina et al[10] | Europeans | 316 (38.4) | 390 (47.4) | 117 (14.2) |
| Kozlitina et al[10] | Hipanics | 163 (37.7) | 209 (48.4) | 60 (13.9) |
| Hyysalo et al[12] | Finns | 145 (33.7) | 190 (44.2) | 95 (22.1) |
| Niu et al[20] | Northern Chinese | 206 (25.8) | 375 (46.9) | 218 (27.3) |
-
Citation: Li MR, Zhang SH, Chao K, Liao XH, Yao JY, Chen MH, Zhong BH.
Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. World J Gastroenterol 2014; 20(38): 14010-14017 - URL: https://www.wjgnet.com/1007-9327/full/v20/i38/14010.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.14010
